Ubiquitin-specific protease 7 (USP7) is a central regulator of multiple oncogenic pathways and is associated with tumor aggressiveness and poor prognosis across several cancer types. Researchers from Molecure SA characterized the preclinical profile of OAT-4828, a selective USP7 inhibitor with antiproliferative activity.